Evidence map›Paper›PMID 26825640›Full record

Trial reportDrug metabolism and disposition: the biological fate of chemicals2016

Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects.

Qing Li, Hong Yang, Dong Guo, Taolan Zhang, James E Polli, Honghao Zhou, Yan Shu

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug metabolism and disposition: the biological fate of chemicals, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Tapping into 5-HTInternational journal of molecular sciences · 2021
    Review
  5. In Vitro Inhibition of Renal OCT2 and MATE1 Secretion by Antiemetic Drugs.International journal of molecular sciences · 2021
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Qing LiDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.) yshu@rx.umaryland.edu qli1026@163.com.
Hong YangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.).
Dong GuoDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.).
Taolan ZhangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.).
James E PolliDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.).
Honghao ZhouDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.).
Yan ShuDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, Maryland (Q.L., H.Y., D.G., J.E.P., Y.S.); Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Hunan, People's Republic of China (Q.L., T.Z., H.Z.) yshu@rx.umaryland.edu qli1026@163.com.
Central South University · CNUniversity of Maryland, Baltimore · USXiangya Hospital Central South University · CN

Funding

University of Maryland Center of Excellence in Regulatory Science and InnovationU01FD004320 · FDA · UNIV OF MARYLAND, COLLEGE PARK · PI BENTLEY, WILLIAM E., POLLI, JAMES E · 2011 to 2016
$3.8M
Xenobiotic Transporter Regulation and IRIP FunctionR01GM099742 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI SHU, YAN · 2012 to 2016
$1.6M
FDA HHS U01 FD004320FDA HHS U01FD004320NIGMS NIH HHS R01 GM099742NIGMS NIH HHS R01GM099742
6 · The paper itself

Abstract

The 5-hydroxytryptamine-3 (5-HT3) receptor antagonists such as ondansetron have been used to prevent and treat nausea and vomiting for over 2 decades. This study was to determine whether ondansetron could serve as a perpetrator drug causing transporter-mediated drug-drug interactions in humans. Twelve unrelated male healthy Chinese volunteers were enrolled into a prospective, randomized, double-blind, crossover study to investigate the effects of ondansetron or placebo on the pharmacokinetics of and the response to metformin, a well-characterized substrate of organic cation transporters and multidrug and toxin extrusions (MATEs). Ondansetron treatment caused a statistically significantly higher Cmax of metformin compared with placebo (18.3 ± 5.05 versus 15.2 ± 3.23; P = 0.006) and apparently decreased the renal clearance of metformin by 37% as compared with placebo (P = 0.001). Interestingly, ondansetron treatment also statistically significantly improved glucose tolerance in subjects, as indicated by the smaller glucose area under the curve in the oral glucose tolerance test (10.4 ± 1.43) as compared with placebo (11.5 ± 2.29 mmol∙mg/l) (P = 0.020). It remains possible that ondansetron itself may affect glucose homeostasis in human subjects, but our clinical study, coupled with our previous findings in cells and in animal models, indicates that ondansetron can cause a drug-drug interaction via its potent inhibition of MATE transporters in humans.

Indexed as

Administration, OralCross-Over StudiesDouble-Blind MethodDrug InteractionsHealthy VolunteersHumansHypoglycemic AgentsMaleMetforminOndansetronOrganic Cation Transport ProteinsProspective StudiesSerotonin 5-HT3 Receptor AntagonistsYoung AdultHypoglycemic AgentsMetforminOndansetronOrganic Cation Transport ProteinsSerotonin 5-HT3 Receptor Antagonists

Identifiers

PMID26825640
PMCPMC4810771
OpenAlexW2288454430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.